Scientific Posters

AES 2020

Ganaxolone Significantly Reduces Major Motor Seizures Associated With CDKL5 Deficiency Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (Marigold Study)

Pharmacokinetic-Pharmacodynamic Analysis of Oral Ganaxolone in Patients with CDKL5 Deficiency Disorder: Results From the Marigold Study

Intravenous Ganaxolone for the Treatment of Refractory Status Epilepticus: Results From an Open-Label, Dose-Finding, Phase 2 Study

IV Ganaxolone in Pediatric Super Refractory Status Epilepticus: A Single Patient Case Study

Ganaxolone Mechanism of Action and Pharmacology

Effect of Ganaxolone on Seizure Frequency Across Subpopulations of Patients With CDKL5 Deficiency Disorder: Subgroup Analyses of the Marigold Study

Status Epilepticus: Inpatient Burden of Illness and Association with Disease Severity

Treatment of Super Refractory Status Epilepticus Using Intravenous Ganaxolone in a Patient with Lennox-Gastaut Syndrome and Angelman Syndrome

A Double-Blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in Status Epilepticus (RAISE)

Extended Duration Safety and Efficacy of Ganaxolone for the treatment of CDKL5 Deficiency Disorder: Preliminary Open-Label Extension Analysis (Marigold Study)

AES 2019

Intravenous Ganaxolone Achieves Rapid and Does-Dependent Sustained Improvement in EEG Seizure Burden in Patients with Refractory with Refractory Status Epilepticus (

Pharmacokinetic and Pharmacodynamic (PK/PD) Relationship of Intravenous Ganaxolone in Refractory Status Epilepticus

Population Pharmacokinetic/Pharmacodynamic Modeling of the Electroencephalographic Effects of Ganaxolone in Healthy Subjects

AES 2018

Ganaxolone in CDKL5 Deficiency Disorder: Open-Label Phase 2a Results and Ongoing Pivotal Phase 3 Study Design

Long-term, Durable Seizure Frequency Reduction in Children with CDKL5 Deficiency Disorder (CDD) Treated with Ganaxolone